Secondary Logo

Share this article on:

Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections

doi: 10.1097/01.NPR.0000546537.12977.08
CE Connection

For more than 275 additional continuing-education articles related to Advanced Practice Nursing topics, go to NursingCenter.com/CE.

Earn CE credit online: Go to www.nursingcenter.com/CE/NP and receive a certificate within minutes.

Back to Top | Article Outline

INSTRUCTIONS Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections

TEST INSTRUCTIONS

  • To take the test online, go to our secure website at www.nursingcenter.com/ce/NP. View instructions for taking the test online there.
  • If you prefer to submit your test by mail, record your answers in the test answer section of the CE enrollment form on page 38. You may make copies of the form.
  • Each question has only one correct answer. There is no minimum passing score required.
  • Complete the registration information and course evaluation. Mail the completed form and registration fee of $17.95 to: Lippincott Professional Development CE Group, 74 Brick Blvd., Bldg. 4, Suite 206, Brick, NJ 08723. We will mail your certificate in 4 to 6 weeks. For faster service, include a fax number and we will fax your certificate within 2 business days of receiving your enrollment form. You will receive your CE certificate of earned contact hours and an answer key to review your results.
  • Registration deadline is September 4, 2020.
Back to Top | Article Outline

DISCOUNTS and CUSTOMER SERVICE

  • Send two or more tests in any nursing journal published by Lippincott Williams & Wilkins together and deduct $0.95 from the price of each test.
  • We also offer CE accounts for hospitals and other healthcare facilities on nursingcenter.com. Call 1-800-787-8985 for details.
Back to Top | Article Outline

PROVIDER ACCREDITATION

Lippincott Professional Development will award 1.5 contact hours for this continuing nursing education activity.

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 1.5 contact hours. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia, Georgia, and Florida CE Broker #50-1223.

This activity has been assigned 1.5 pharmacology credits.

Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections

Purpose: To provide information on the role of lipoglycopeptides and other standardized therapy options used to treat ABSSSIs. Learning Objectives/Outcomes: After completing this continuing-education activity, you should be able to: 1. Outline the epidemiology of ABSSSIs and current therapy and monitoring parameters. 2. Identify the role of oritavancin and dalbavancin in the treatment of ABSSSIs.

  1. Based on the FDA current guidance practices, the terminology change to ABSSSI describes
    1. complicated infections that require surgery.
    2. infections associated with resistant organisms.
    3. infections that are appropriate for treatment with lipoglycopeptides.
  2. Which statement about ABSSSIs is correct?
    1. ABSSSI admissions are more common than community-acquired pneumonia.
    2. ABSSSIs have declined over the last 5 years.
    3. ABSSSI hospitalizations are most common with Pseudomonas species.
  3. According to the Infectious Disease Society of America, which is the first-line treatment for nonpurulent cellulitis?
    1. daptomycin
    2. telavancin
    3. vancomycin
  4. The use of I.V. infusion vancomycin is suboptimal in the outpatient setting due to
    1. increased risk of developing resistant organism.
    2. multiple daily dose requirements.
    3. risk of hematologic abnormalities.
  5. Increases in the minimum inhibitory concentration of an antibiotic over time can result in all the following except:
    1. fewer resistant organisms.
    2. failure to inhibit the bacteria.
    3. higher dose requirements.
  6. Which baseline lab value helps monitor patients receiving daptomycin?
    1. coagulation studies
    2. creatine phosphokinase
    3. liver function profile
  7. Urine myoglobin should be monitored when the clinician suspects
    1. end-stage renal disease.
    2. hepatic failure.
    3. rhabdomyolysis.
  8. Which statement about telavancin is correct?
    1. Derived from vancomycin, this once-daily drug is less costly than its precursor.
    2. Its mechanism of action is similar to vancomycin and is an option when once-daily dosing is desired.
    3. Oral and I.V. infusion formulas have equal success rates with treating ABSSSIs.
  9. Which of the following is a black box warning for telavancin?
    1. nephrotoxicity
    2. prolonged QT interval
    3. thrombocytopenia
  10. Which antibiotic is not significantly metabolized by the kidney or liver?
    1. daptomycin
    2. oritavancin
    3. vancomycin
  11. The slow release from tissues gives oritavancin a terminal half-life of
    1. 147 hours.
    2. 258 hours.
    3. 393 hours.
  12. Blood concentration monitoring for oritavancin is
    1. indicated prior to the second dose.
    2. indicated weekly.
    3. not indicated.
  13. After the administration of oritavancin, the use of unfractionated heparin sodium is contraindicated for
    1. 3 days.
    2. 5 days.
    3. 12 days.
  14. Osteomyelitis is an increased risk for patients who are taking
    1. oritavancin.
    2. dalbavancin.
    3. vancomycin.
  15. If a two-dose regimen of dalbavancin is planned, the second dose would be administered
    1. 5 days after the initial dose.
    2. 7 days after the initial dose.
    3. 10 days after the initial dose.
  16. When treating ABSSSIs with dalbavancin, it is recommended that the NP monitor the patient for
    1. clinical response in 2 to 3 days.
    2. signs and symptoms of osteomyelitis in 7 days.
    3. therapeutic level weekly.
  17. According to this article, treatment of resistant staphylococcal infections is challenging in the pediatric population because dalbavancin and oritavancin
    1. have limited exposure in pediatric populations.
    2. have been shown to be less effective in pediatric population.
    3. have increased risk of nephrotoxicity in the pediatric population.
  18. The benefit of dalbavancin and oritavancin when compared with standard treatments for severe ABSSSIs include
    1. daily dosing.
    2. dose adjustment options for kidney disease.
    3. sparing the need for hospitalization.
Figure

Figure

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.